-
平臺編號：bio-68410
-
國際編號：CRL-2370?
-
細(xì)胞信息： C1R-sB7
-
規(guī)格：frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費用：
加載中…… - 訂購
-
注意事項：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準(zhǔn)）
C1R-sB7
細(xì)胞類型：B淋巴細(xì)胞
是否是腫瘤細(xì)胞：0
物種來源：人
生長狀態(tài)：混合型生長
ATCC Number：CRL-2370?
運輸方式：凍存運輸
細(xì)胞形態(tài)：淋巴樣
器官來源：外周血
數(shù)量：大量
規(guī)格：0.1ml Designations: C1R-sB7
Depositors: ?F Grumet
Biosafety Level:2 [Cells contain Herpesvirus ]
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:mixed; semi-attached
Organism: Homo sapiens
Morphology:lymphoblast
Source: Organ: peripheral blood
Cell Type: B lymphoblast; Epstein-Barr virus (EBV) transformed
Cellular Products:Secretes HLA B7 but does not express surface HLA B7
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
DNA Profile (STR):Amelogenin: X
CSF1PO: 6,10
D13S317: 11,13
D16S539: 9,13
D5S818: 10,13
D7S820: 7,12
THO1: 8
TPOX: 8
vWA: 17
Comments:C1R-sB7 is a stable transfectant cell line established in 1988 with a modified histocompatibility complex (MHC) HLA B7 gene. It secretes HLA B7 but does not express surface HLA B7. [38581 ]
C1R-sB7 was established by transfection by electroporation of the C1R cell line with a modified neomycin drug-resistant eukaryotic vector, pSP65-Neo carrying the gene for soluble B7 (sB7). It was selected in geneticin and cloned by limiting dilution.
C1R is a human B-cell lymphoblastoid line lacking surface HLA A and B antigens. C1R was derived from Hmy.2 B-LCL by gamma irradiation followed by selection for Class I monoclonal antibodies and complement. [23312 ]
C1R-sB7 has been a reference standard in International Workshops on soluble HLA.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by transferring floating cells to additional flasks.
Attached cells may be subcultured by scraping.
Preservation: culture medium 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2005
recommended serum:ATCC 30-2020
parental cell line:ATCC CRL-1993
derived from same cell line:ATCC CRL-2369
derived from same cell line:ATCC CRL-2371
References: 23312: Storkus WJ, et al. Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc. Natl. Acad. Sci. USA 86: 2361-2364, 1989. PubMed: 2784569
38581: Grumet FC, et al. Soluble form of an HLA-B7 class I antigen specifically suppresses humoral alloimmunization. Hum. Immunol. 40: 228-234, 1994. PubMed: 7960967
38582: Hiraki DD, et al. Bioengineered soluble HLA-B7. Genesis, characterization, and occurrence of dimerization. Hum. Immunol. 40: 235-246, 1994. PubMed: 7960968
38583: Grumet FC, et al. Report of the second international soluble HLA (sHLA) workshop. Phoenix, Arizona, October 2, 1993. Hum. Immunol. 40: 153-165, 1994. PubMed: 7960956
是否是腫瘤細(xì)胞：0
物種來源：人
生長狀態(tài)：混合型生長
ATCC Number：CRL-2370?
運輸方式：凍存運輸
細(xì)胞形態(tài)：淋巴樣
器官來源：外周血
數(shù)量：大量
規(guī)格：0.1ml Designations: C1R-sB7
Depositors: ?F Grumet
Biosafety Level:2 [Cells contain Herpesvirus ]
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:mixed; semi-attached
Organism: Homo sapiens
Morphology:lymphoblast
Source: Organ: peripheral blood
Cell Type: B lymphoblast; Epstein-Barr virus (EBV) transformed
Cellular Products:Secretes HLA B7 but does not express surface HLA B7
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
DNA Profile (STR):Amelogenin: X
CSF1PO: 6,10
D13S317: 11,13
D16S539: 9,13
D5S818: 10,13
D7S820: 7,12
THO1: 8
TPOX: 8
vWA: 17
Comments:C1R-sB7 is a stable transfectant cell line established in 1988 with a modified histocompatibility complex (MHC) HLA B7 gene. It secretes HLA B7 but does not express surface HLA B7. [38581 ]
C1R-sB7 was established by transfection by electroporation of the C1R cell line with a modified neomycin drug-resistant eukaryotic vector, pSP65-Neo carrying the gene for soluble B7 (sB7). It was selected in geneticin and cloned by limiting dilution.
C1R is a human B-cell lymphoblastoid line lacking surface HLA A and B antigens. C1R was derived from Hmy.2 B-LCL by gamma irradiation followed by selection for Class I monoclonal antibodies and complement. [23312 ]
C1R-sB7 has been a reference standard in International Workshops on soluble HLA.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by transferring floating cells to additional flasks.
Attached cells may be subcultured by scraping.
Preservation: culture medium 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2005
recommended serum:ATCC 30-2020
parental cell line:ATCC CRL-1993
derived from same cell line:ATCC CRL-2369
derived from same cell line:ATCC CRL-2371
References: 23312: Storkus WJ, et al. Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc. Natl. Acad. Sci. USA 86: 2361-2364, 1989. PubMed: 2784569
38581: Grumet FC, et al. Soluble form of an HLA-B7 class I antigen specifically suppresses humoral alloimmunization. Hum. Immunol. 40: 228-234, 1994. PubMed: 7960967
38582: Hiraki DD, et al. Bioengineered soluble HLA-B7. Genesis, characterization, and occurrence of dimerization. Hum. Immunol. 40: 235-246, 1994. PubMed: 7960968
38583: Grumet FC, et al. Report of the second international soluble HLA (sHLA) workshop. Phoenix, Arizona, October 2, 1993. Hum. Immunol. 40: 153-165, 1994. PubMed: 7960956
